nach oben

Erschienen in:

19.04.2020 | Krebserkrankungen mit unbekanntem Primärtumor | Zertifizierte Fortbildung

Definition, Biologie, Diagnostik und Therapie

Das CUP-Syndrom - Stand 2020

verfasst von: Maria Pouyiourou, Laura Claßen, Göran R. Boeckel, Tilmann Bochtler, Alwin Krämer

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Auszug

Bei circa 3-5 % aller Tumorerkrankungen lässt sich trotz umfänglicher Diagnostik kein Primarius, sondern nur eine Metastasierung identifizieren. Dieses sogenannte CUP-Syndrom stellt Behandler vor große Herausforderungen, insbesondere wenn ein prognostisch ungünstiger Subtyp vorliegt. Lesen Sie im Folgenden, wie der aktuelle Stand in puncto Biologie, Diagnostik und Therapie aussieht. Vor allem eine verfeinerte Identifikation von molekularen Targets und Markern macht Hoffnung, die CUP-Behandlung zukünftig verbessern zu können. …

Fizazi K et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133-8

Krämer A et al. Biologic Features of CUP. In: Krämer A, Löffler H (Hrsg.). Cancer of Unknown Primary. Springer International Publishing Switzerland, 2016

Löffler H et al. [Cancer of unknown primary. Epidemiology and pathogenesis]. Radiologe. 2014;54(2):107-11

Pentheroudakis G et al. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43(14):2026-36

Bochtler T et al. Integrated clinico-molecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Int J Cancer. 2020; https://doi.org/10.1002/ijc.32882

Hemminki K et al. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012;23(7):1854-63

van de Wouw AJ et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38(3):409-13

Schroten-Loef C et al. Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012. Eur J Cancer. 2018;101:77-86

Krämer A et al. Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions. J Clin Oncol. 2018;36(15_suppl):Abstr e24162

10.

Gatalica Z et al. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer. 2018;94:179-86

11.

Varghese AM et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol. 2017;28(12):3015-21

12.

Löffler H et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016;7(28):44322-9

13.

Ross JS et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015;1(1):40-9

14.

Stenzinger A et al. [The role of pathology in the diagnostics of CUP syndrome]. Radiologe. 2014;54(2):124-33

15.

Dumur CI et al. Clinical verification of the performance of the pathwork tissue of origin test: utility and limitations. Am J Clin Pathol. 2011;136(6):924-33

16.

Monzon FA et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27(15):2503-8

17.

van Laar RK et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer. 2009;125(6):1390-7

18.

Tothill RW et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Rea. 2005;65(10):4031-40

19.

Handorf CR et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol. 2013;37(7):1067-75

20.

Kulkarni A et al. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer. Diagn Pathol. 2012;7:110

21.

Weiss LM et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn. 2013;15(2):263-9

22.

Greco FA et al. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst. 2013;105(11):782-90

23.

Seve P et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109(2):292-9

24.

Moller AK et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist. 2012;17(9):1146-54

25.

Roh JL et al. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol. 2009;45(3):218-24

26.

Reinert CP et al. Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study. Eur Radiol. 2020;30(3):1325-33

27.

Culine S et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21(18):3479-82

28.

Palmeri S et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer. 2006;107(12):2898-905

29.

Huebner G et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009;100(1):44-9

30.

Hainsworth JD et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010;16(1):70-5

31.

Gross-Goupil M et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012; 48(5):721-7

32.

Hainsworth JD et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer. 2015;121(10):1654-61

33.

Lee J et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer. 2013;108(1):39-48

34.

Valle JW et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009;101(4):621-7

35.

Hayashi H et al. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin Oncol. 2019;37(7):570-9

36.

Fizazi K et al. A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary site (GEFCAPI 04). Ann Oncol. 2019;30(suppl_5):v851-v934

37.

Culine S et al. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res. 2001;21(2B):1455-7

38.

Hainsworth JD et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2001;19(4):335-9

39.

Pouessel D et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23(3C):2801-4

40.

Hainsworth JD et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2005;104(9):1992-7

41.

Moller AK et al. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol. 2010;49(4):431-5

42.

Hainsworth, JD et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(10):2448-54

43.

Hainsworth JD et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007;25(13):747-52

44.

Bochtler T et al. Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity? Front Oncol. 2019;9:402

45.

Kolling S et al. "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"? Front Oncol. 2019;9:1546

46.

Pentheroudakis G et al. Cancer of unknown primary site: missing primary or missing biology? Oncologist. 2007;12(4):418-25

47.

Gatalica Z et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 2014;5(23):12440-7

48.

Tothill RW et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013;231(4):413-23

49.

Gay LM et al. Mutational burden of tumors with primary site unknown. J Clin Oncol. 2017;35(15_suppl):Abstr 3039

50.

Yarchoan M et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500-1

51.

Gröschel S et al. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud. 2016;2(6):a001180

52.

Palma NA et al. Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Rep Oncol. 2014;7(2):503-8

53.

Tan DS et al. Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. J Clin Oncol. 2013;31(14):e237-9

Titel: Definition, Biologie, Diagnostik und Therapie
Das CUP-Syndrom - Stand 2020
verfasst von: Maria Pouyiourou
Laura Claßen
Göran R. Boeckel
Tilmann Bochtler
Alwin Krämer
Publikationsdatum: 19.04.2020
Verlag: Springer Medizin
Schlagwort: Krebserkrankungen mit unbekanntem Primärtumor
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 4/2020
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-020-8068-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Das CUP-Syndrom - Stand 2020

Auszug

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Wie den PD-L1-Status bestimmen?

mUC: Überlebensvorteil durch Atezolizumab

CAR-T-Zell-Präparat: Aussichtsreiche Option

CDK4/6-Inhibition: Klinisch hochrelevante Verlängerung des PFS auch in Subgruppen

Sport verlängert das Leben bei Brustkrebs

ITP: Eltrombopag in neuer Darreichungsform

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie